A randomized phase II study of leucovorin/5-fluorouracil with or without oxaliplatin (LV5FU2 vs. FOLFOX) for curatively-resected, node-positive esophageal squamous cell carcinoma

Cancer Research and Treatment

Volumn 49, Issue 3, 2017, Pages 816-823

  Lim, Sung Hee ^a,b   Shim, Young Mog ^b   Park, Se Hoon ^b   Kim, Hong Kwan ^b   Choi, Young Soo ^b   Ahn, Myung Ju ^b   Park, Keunchil ^b   Zo, Jae Ill ^b   Sun, Jong Mu ^b  

^a Hallym University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Adjuvant chemotherapy; Esophageal neoplasms; FOLFOX

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASPIRATION PNEUMONIA; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CERVICAL LYMPH NODE METASTASIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; ADJUVANT CHEMOTHERAPY; CANCER GRADING; CLINICAL TRIAL; ESOPHAGUS TUMOR; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 85022006228     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2016.417     Document Type: Article

References (18)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Oh CM, Won YJ, Jung KW, Kong HJ, Cho H, Lee JK, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat. 2016;48:436-50.
3. Layke JC, Lopez PP. Esophageal cancer: a review and update. Am Fam Physician. 2006;73:2187-94.
4. Steup WH, De Leyn P, Deneffe G, Van Raemdonck D, Coosemans W, Lerut T. Tumors of the esophagogastric junction: long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. J Thorac Cardiovasc Surg. 1996;111: 85-94.
5. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681-92.
6. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-84.
7. Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16: 1090-8.
8. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062-7.
9. Yano M, Motoori M, Tanaka K, Kishi K, Fujiwara Y, Shingai T, et al. Preoperative staging of clinically node-negative esophageal cancer by the combination of 18F-fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT). Esophagus. 2012;9:210-6.
10. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study: JCOG-9204. J Clin Oncol. 2003;21:4592-6.
11. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33:1216-20.
12. Shiozaki A, Yamagishi H, Itoi H, Fujiwara H, Kikuchi S, Okamoto K, et al. Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer. Oncol Rep. 2005;13:667-72.
13. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68-74.
14. Pasquali S, Yim G, Vohra RS, Mocellin S, Nyanhongo D, Marriott P, et al. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis. Ann Surg. 2017;265: 481-91.
15. Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15:305-14.
16. Mauer AM, Kraut EH, Krauss SA, Ansari RH, Kasza K, Szeto L, et al. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol. 2005;16:1320-5.
17. Hsu PK, Huang CS, Wang BY, Wu YC, Hsu WH. Survival benefits of postoperative chemoradiation for lymph node-positive esophageal squamous cell carcinoma. Ann Thorac Surg. 2014;97:1734-41.
18. Lee J, Lee KE, Im YH, Kang WK, Park K, Kim K, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 2005;80:1170-5.